Teclison, Inc. to Participate in ASCO Gastrointestinal Cancers Symposium
PRINCETON, N. J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Teclison, Inc., a clinical-stage oncology company dedicated to advancing immunotherapeutic treatments for solid tumors, today announced that Ray Lee, chief executive officer and co-founder of Teclison will participate in the ASCO Gastrointestinal Cancers Symposium on January 9th.
ASCO Gastrointestinal Cancers Symposium
Date: Friday, January 9, 2026
Location: Moscone West, San Francisco, CA 94103 and Virtual
About Teclison
Teclison is a clinical stage oncology company advancing an immunotherapy treatment for solid tumors utilizing a three-pronged approach that: (1) induces tumor necrosis; (2) expands anti-tumor T cells to synergize with immune checkpoint inhibitors; and (3) facilitates the direct and cost-effective expansion of anti-tumor immunity from PBMCs. Teclison’s innovative platform has shown broad reach across solid tumor types in clinical trials, providing Teclison access to numerous multi-billion dollar markets. Teclison’s lead asset, TEC-001, is initially targeting primary liver cancer, with additional cancer indications in the pipeline. For more information, please visit teclison.com.
Contacts:
Diane Lu
Chief Financial Officer
info@teclison.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
